CD19 and Miyoshi myopathy: As shown in Figure A4, higher any grade NS event incidences were observed in CD19-ALL (44%; 95% CI, 23–65%), CD19-NHL (49%; 95% CI, 18–80%), CD20-ALL (72%; 95% CI, 68–76%), CD22-ALL (45%; 95% CI, 41–50%) and BCMA-MM (34%; 95% CI, 24–43%).